Information  X 
Enter a valid email address

ValiRx interim loss narrows

By BFN News | 08:03 AM | Tuesday 26 September, 2017

ValiRx has booked a narrower first-half loss after receiving R&D Tax Credits of around £650,000. Its loss before tax reduced slightly by 2.6% to £2.25m. The total comprehensive loss for the period was £1.99m, narrowing from £2.07m. "We have seen considerable progress across our therapeutic portfolio in the last 6 months, adding value to the company's assets and bringing us closer to the point where our clinical programmes for VAL201 and VAL401 will deliver meaningful data and will bring the company closer to finding a partner," ValiRx Chairman Oliver de Giorgio-Miller said. At 8:03am: (LON:VAL) ValiRx PLC share price was 0p at 1.03p Story provided by

a d v e r t i s e m e n t